1. /
  2. About us /
  3. Our people and structure /
  4. Our people /
  5. Rachel Sacks-Davis
Our people

Dr Rachel Sacks-Davis

Senior Research Fellow

Taking students

Working groups

rachel.sacks-davis@burnet.edu.au
Dr Rachel Sacks-Davis

Background

Dr Rachel Sacks-Davis is a Senior Research Fellow at the Burnet Institute in the Disease Elimination Program. She is the Senior Manager of the International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC). After completing her BA (Hons)/BSc Rachel joined Burnet as a Research Assistant in 2008.

From 2010-2014 she completed her PhD in epidemiology at the Burnet Institute on hepatitis C transmission and natural history amongst people who inject drugs. She was awarded an NHMRC Early Career Fellowship (2016-2021), which allowed her to play a leadership role in the formation of the InCHEHC collaboration.

Qualifications

  • PhD (Epidemiology), Monash University, Australia
  • BA(Hons), Monash University, Australia
  • BA/BSc, University of Melbourne, Australia

Appointments

  • Adjunct Research Fellow, Monash University
  • Adjunct Fellow, University of Melbourne

Awards

  • 2024: Lady Potter, Burnet Emerging Leader Fellowship
  • 2022: IAS/MSD Prize for Research in HIV Prevention
  • 2012: Harold Mitchell Travel Fellowship
  • 2012: Best poster, 17th International Bioinformatics Workshop, Belgrade
  • 2012: Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine Junior Researcher Award
  • 2011: Robert Blain Memorial Travel Fellowship
  • 2011: European Association of the Study of the Liver Young Investigator Award

Positions

  • 2023: Senior Research Fellow
  • 2021: Research Fellow
  • 2018: NHMRC Early Career Research Fellow
  • 2014: Research Officer

Reports and other work

  • A systematic review of immediate HCV RNA testing following HCV Antibody compared with HCV RNA testing at time of assessment for HCV therapy.

    The World Health organization estimates that between 130 and 150 million people are chronically infected with hepatitis C virus (HCV) worldwide (World Health Organisation, 2012, Woodall et al., 1994). People with untreated HCV are at increased risk of liver cirrhosis, hepatocellular carcinoma, and liver-related mortality (Villano et al., 1997). HCV RNA testing, which generally follows a positive anti-HCV antibody test in a clinical setting, allows the detection of current HCV infection, thus indicating individuals for treatment and care options (Rongey et al., 2009, Scott et al., 2006, Piasecki et al., 2004). This review investigates the optimal time at which to perform HCV RNA tests in order to establish the presence of current infection, and to reduce morbidity and mortality associated with HCV infection.

    A systematic review of immediate HCV RNA testing following HCV Antibody compared with HCV RNA testing at time of assessment for HCV therapy.

  • Modelling the Victorian roadmap (PUBLIC HEALTH REPORT)

    COVID-19 mathematical modelling of the Victoria roadmap 2021.

    Modelling the Victorian roadmap (PUBLIC HEALTH REPORT)

Burnet publications

View 118 more
20 Feb 2025

Liver fibrosis regression in people living with HIV after successful treatment for hepatitis C

JAIDS Journal of Acquired Immune Deficiency Syndromes

Rachel Sacks‐Davis, Ashleigh C. Stewart, Daniela K van Santen, Joseph Doyle, Mark Stoové, Margaret Hellard

Open access
10 Dec 2024

Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort

Liver International

Brendan Harney, Rachel Sacks‐Davis, Daniëla K. van Santen, Ashleigh C. Stewart, Margaret Hellard, Joseph Doyle

Open access
30 Nov 2024

Phenotyping people with a history of injecting drug use within electronic medical records using an interactive machine learning approach

npj Digital Medicine

Carol El‐Hayek, Thi Nguyen, Margaret Hellard, M. David Curtis, Rachel Sacks‐Davis, Jason Asselin, Anna L. Wilkinson, Victoria Polkinghorne

Open access

Current projects

View 3 more
EXPAND-C: hepatitis C testing and treatment through community pharmacies

EXPAND-C: hepatitis C testing and treatment through community pharmacies

Expanding access to hepatitis C testing and treatment using a pharmacy-based model.

Hepatitis C modelling

Hepatitis C modelling

Our modelling aims to help countries identify the most effective and cost-effective ways to eliminate hepatitis C as a public health threat.

International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)
Open to students

International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)

This is a multinational longitudinal cohort of people living with HIV who are at risk of hepatitis C virus infection or infected with the hepatitis C virus.

View 3 more

Past projects

View 2 more
The elimination of hepatitis C as a global public health threat

The elimination of hepatitis C as a global public health threat

This project addresses critical knowledge gaps in Australian and global efforts to eliminate hepatitis C as a public health threat by 2030.

The Optimise Study: Optimising Isolation, Quarantine and Distancing for COVID-19

The Optimise Study: Optimising Isolation, Quarantine and Distancing for COVID-19

This project aims to find out how Victorians are experiencing COVID-19 and responding to the measures introduced to stop the spread of the virus.

Transparent risk assessment of COVID-19 quarantine (traQ study)

Transparent risk assessment of COVID-19 quarantine (traQ study)

This study uses a mathematical model to examine the circumstances in which quarantine for COVID-19 could be reduced from 14 days without substantially increasing the risk of virus transmission.

View 2 more

News and features

Lady Potter, Burnet Emerging Leader Fellowships

Lady Potter, Burnet Emerging Leader Fellowships

On this page